Incidence of grades 2 to 4 nonhematologic toxicities during remission induction therapy with intensive chemotherapy and imatinib
Adverse event . | Grade 2, no. (%) . | Grade 3, no. (%) . | Grade 4, no. (%) . |
|---|---|---|---|
| Sepsis | 0 | 3 (13) | 0 |
| Other febrile neutropenia | 1 (4) | 6 (26) | 0 |
| Symptomatic CMV infection | 0 | 2 (8) | 0 |
| Lung hemorrhage | 1 (4) | 0 | 1 (4) |
| Diarrhea | 1 (4) | 1 (4) | 0 |
| Ileus | 1 (4) | 2 (8) | 0 |
| Nausea | 1 (4) | 4 (17) | 0 |
| GPT | 4 (17) | 3 (13) | 0 |
| Jaundice | 1 (4) | 0 | 0 |
| Pancreatitis | 0 | 1 (4) | 0 |
| Hyperglycemia | 2 (8) | 1 (4) | 0 |
| Hypophosphatemia | 1 (4) | 0 | 0 |
| Hypokalemia | 0 | 1 (4) | 0 |
| Fluid retention | 1 (4) | 0 | 0 |
| Depression | 3 (13) | 0 | 0 |
| Muscle weakness | 0 | 1 (4) | 0 |
Adverse event . | Grade 2, no. (%) . | Grade 3, no. (%) . | Grade 4, no. (%) . |
|---|---|---|---|
| Sepsis | 0 | 3 (13) | 0 |
| Other febrile neutropenia | 1 (4) | 6 (26) | 0 |
| Symptomatic CMV infection | 0 | 2 (8) | 0 |
| Lung hemorrhage | 1 (4) | 0 | 1 (4) |
| Diarrhea | 1 (4) | 1 (4) | 0 |
| Ileus | 1 (4) | 2 (8) | 0 |
| Nausea | 1 (4) | 4 (17) | 0 |
| GPT | 4 (17) | 3 (13) | 0 |
| Jaundice | 1 (4) | 0 | 0 |
| Pancreatitis | 0 | 1 (4) | 0 |
| Hyperglycemia | 2 (8) | 1 (4) | 0 |
| Hypophosphatemia | 1 (4) | 0 | 0 |
| Hypokalemia | 0 | 1 (4) | 0 |
| Fluid retention | 1 (4) | 0 | 0 |
| Depression | 3 (13) | 0 | 0 |
| Muscle weakness | 0 | 1 (4) | 0 |
CMV indicates cytomegalovirus.